Lexeo Therapeutics (LXEO) Free Cash Flow (2022 - 2026)

Lexeo Therapeutics has reported Free Cash Flow for 5 years, with the latest figure at -$21.2 million in Q1 2026.

• Quarterly Free Cash Flow rose 2.47% year-over-year to -$21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.3 million (down 11.34% YoY) and the FY2025 annual result came in at -$99.0 million, down 21.22% from the prior year.
• Free Cash Flow eased to -$21.2 million in Q1 2026 per LXEO's latest filing, from -$20.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$13.2 million in Q2 2023 and troughed at -$29.8 million in Q3 2025.
• A 5-year average of -$19.8 million and a median of -$19.2 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 101.55% in 2024, then gained 29.11% in 2025.
• Over 5 years, Free Cash Flow stood at -$16.5 million in 2022, then rose by 14.94% to -$14.1 million in 2023, then tumbled by 101.55% to -$28.3 million in 2024, then increased by 29.11% to -$20.1 million in 2025, then slipped by 5.48% to -$21.2 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$21.2 million, -$20.1 million, and -$29.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.